胸外科手术在转移性非小细胞肺癌治疗管理中的作用
这篇叙述性综述总结了IV期非小细胞肺癌多学科治疗中外科干预的文献,聚焦寡转移和胸膜转移患者行治疗性或根治性手术的证据。在经选择的患者中,手术切除可使5年生存率达30%至50%,但受纵隔淋巴结病变影响,术前应评估。诊断或姑息手术在个体化治疗中也有重要作用。
要点
- IV期NSCLC总体5年生存率仍低,为4%至6%。
- 经选择患者手术切除后5年生存率为30%至50%,但受纵隔淋巴结病变影响。
- 诊断或姑息手术在IV期个体化治疗中可发挥重要作用。
核心结论
- 在经仔细选择的晚期NSCLC患者中,外科干预可作为综合治疗的重要组成部分。
- 鉴于分子靶向治疗和免疫治疗的进展,进一步研究应聚焦于手术作为治疗性「巩固」策略用于接受综合治疗的适宜选择的IV期NSCLC患者的可能性。
研究设计与样本
- 叙述性综述,总结IV期NSCLC多学科治疗中外科干预的文献,聚焦寡转移和胸膜转移患者治疗性或根治性手术的潜在支持与反对证据。
主要发现
- 在经选择的患者中,手术切除可带来30%至50%的5年生存率,但这受纵隔淋巴结病变存在的显著影响,应在进行治疗性手术前评估。
- 诊断或姑息性手术可在IV期疾病的个体化治疗中发挥重要作用。
关键数值与推荐
- IV期NSCLC总体5年生存率仍低,为4%至6%。
- 经选择患者手术切除后5年生存率为30%至50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In most patients with NSCLC, the disease is diagnosed in an advanced stage, the prognosis is poor, and survival is typically measured in months. Standard therapeutic treatment regimens for patients with stage IV NSCLC typically include chemotherapy and palliative radiation. Despite newer regimens that may include molecularly targeted therapy and immunotherapy, the overall 5-year survival for stage IV disease remains low at 4% to 6%. Although therapeutic surgery is performed in a minority of cases, accumulating data suggest that thoracic surgery may play several beneficial roles for these patients. METHODS: In this narrative review, we summarize the literature on surgical intervention in the multimodality management of stage IV NSCLC, focusing on the potential evidence for and against therapeutic or curative intent procedures to affect outcomes for patients with oligometastatic disease and pleural metastasis. RESULTS: In selected patients, surgical resection can result in a 5-year survival rate of 30% to 50%, but this is heavily influenced by the presence of mediastinal nodal disease, which should be evaluated before therapeutic surgical procedures are undertaken. Additionally, diagnostic or palliative surgical procedures can play an important role in the personalized management of stage IV disease. These data suggest that for carefully selected patients with advanced stage NSCLC, surgical intervention can be an important component of combined modality treatment. CONCLUSIONS: Given the advances in molecular targeted therapy and immunotherapy, further studies should focus on the possible use of surgery as a strategy of therapeutic "consolidation" for appropriately selected patients with stage IV NSCLC who are receiving combined modality care.
引用
- David EA, Clark JM, Cooke DT, et al. The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2017. PMID: 28843357. doi:10.1016/j.jtho.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。